CallTower Named Cloud-Connected Calling Enablement Leader 2024 by Frost & Sullivan
16. Januar 2024 03:05 ET
|
CallTower, Inc.
SALT LAKE CITY, UT, ROCHESTER, NY, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CallTower, a global leader in delivering enterprise-class cloud communication solutions, was recognized by Frost & Sullivan...
CareCloud Named Summer 2023 Market Leader for Medical Practice Management Software and Receives 2023 Top Rated Software Award from FeaturedCustomers.com
10. Oktober 2023 09:00 ET
|
CareCloud, Inc
SOMERSET, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today...
VERB SELLS ITS DIRECT SALES BUSINESS ASSETS TO FOCUS ON ITS MARKET.LIVE LIVESTREAM SHOPPING BUSINESS
20. Juni 2023 09:00 ET
|
Verb Technology Company, Inc.
NEWPORT BEACH, Calif. and LEHI, UT, June 20, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the leader in interactive video-based sales-enablement...
Verb Technology Company, Inc. Prices $7.2 Million Underwritten Public Offering of Common Stock
24. Januar 2023 09:15 ET
|
Verb Technology Company, Inc.
NEWPORT BEACH, Calif. and LEHI, Utah, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (NASDAQ: VERB) ("VERB" or the "Company"), the leader in interactive video-based sales-enablement...
Hyloris Pharmaceuticals élargit son portefeuille avec un produit candidat pour le traitement de la déficience minérale dans le sang (l’hypophosphatémie)
20. Januar 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
- Hyloris vise à obtenir l’approbation réglementaire en Europe, avec des extensions hors Europe possibles - Environ 5% des patients hospitalisés est diagnostiqué chaque année en hypophosphatémie1,...
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)
20. Januar 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part of them needing direct treatment during...
Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Spray Nasal pour la Rhinite Idiopathique
22. November 2022 12:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Produit Candidat Intranasal Propriétaire d'un Agoniste TRPV11 (HY-083) pour la Rhinite Idiopathique - Hyloris cible une...
Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
22. November 2022 12:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals Broadens Pipeline with a Proprietary Intranasal Product Candidate of a TRPV11 agonist (HY-083) for Idiopathic Rhinitis Hyloris targets a condition that affects up to 7% of...
Greater Cannabis CEO to be Interviewed Today on Yahoo Finance Live at 12:40pm EST
23. September 2019 08:56 ET
|
The Greater Cannabis Company, Inc.
CEO will appear on the On The Move show to discuss Company’s technology as a high-tech alternative to vaping devices, why the GCANRx patch is safer, and what’s in the pipeline for the future. ...
Millicom invests to become the clear market leader in Panama and Central America
09. September 2019 20:38 ET
|
Millicom International Cellular S.A.
Millicom invests to become the clear market leader in Panama and Central America • Millicom has already invested more than $2 billion to enter Panama and plans to invest an additional $750 million...